Skip to main content

Xenon Pharmaceuticals Inc(XENE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low38.75
Day High40.66
Open:40.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
GlobeNewswire
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
GlobeNewswire
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
GlobeNewswire
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
GlobeNewswire
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
GlobeNewswire
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
GlobeNewswire
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
GlobeNewswire
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
GlobeNewswire
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
GlobeNewswire
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
GlobeNewswire
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
GlobeNewswire
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Profile

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.